Cognitive remission: a novel objective for the treatment of major depression?
Beatrice Bortolato, Kamilla W Miskowiak, Cristiano A Koehler, Michael Maes, Brisa S Fernandes, Michael Berk, Andre F Carvalho
BMC MEDICINE | BMC | Published : 2016
BACKGROUND: Cognitive dysfunction in major depressive disorder (MDD) encompasses several domains, including but not limited to executive function, verbal memory, and attention. Furthermore, cognitive dysfunction is a frequent residual manifestation in depression and may persist during the remitted phase. Cognitive deficits may also impede functional recovery, including workforce performance, in patients with MDD. The overarching aims of this opinion article are to critically evaluate the effects of available antidepressants as well as novel therapeutic targets on neurocognitive dysfunction in MDD. DISCUSSION: Conventional antidepressant drugs mitigate cognitive dysfunction in some people wit..View full abstract
Awarded by NHMRC Senior Principal Research Fellowship
AFC is supported by a research fellowship award from the Conselho Nacional de Desenvolvimento Cientifico e Tencnologico (CNPq, Level II, Brazil). CAK is supported by a postdoctoral fellowship from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES, Brazil). MB is supported by a NHMRC Senior Principal Research Fellowship 1059660.